sequenom inc (SQNM:NASDAQ GS)
sequenom inc (SQNM) Snapshot
|
Open
$4.05
|
Previous Close
$4.06
|
|
|
Day High
$4.13
|
Day Low
$3.87
|
|
|
52 Week High
01/7/13 - $5.36
|
52 Week Low
08/2/12 - $2.65
|
|
|
Market Cap
450.2M
|
Average Volume 10 Days
3.4M
|
|
|
EPS TTM
$-1.07
|
Shares Outstanding
115.2M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
sequenom inc (SQNM) Details
Sequenom, Inc., a life sciences company, provides genetic analysis solutions in the United States and internationally. It operates through two segments, Molecular Diagnostics and Genetic Analysis. The Molecular Diagnostics segment researches, develops, and commercializes various noninvasive molecular diagnostic tests for prenatal genetic disorders and diseases; women’s health related disorders and diseases; and ophthalmologic, oncologic, and other medical conditions, such as autoimmunity and neurology. The Genetic Analysis segment offers Mass ARRAY system, a nucleic acid analysis research-use only system that measures genetic target material and variations; and research use only iPLEX multiplexing assay, which permits multiplexed single nucleotide polymorphism (SNP) and somatic mutation analysis. Its MassARRAY systems are used in a range of DNA/RNA analysis applications, including SNP, genotyping, detection of mutations, analysis of copy number variants, and other structural genome variations, as well as in quantitative gene expression analysis, quantitative DNA methylation analysis, comparative sequence analysis of haploid organisms, SNP discovery, and oligonucleotide quality control. This segment also provides contract research services to clinical research laboratories, bioagriculture, biotechnology and pharmaceutical companies, academic institutions, and government agencies. The company was founded in 1994 and is headquartered in San Diego, California.
sequenom inc (SQNM) Top Compensated Officers
sequenom inc (SQNM) Key Developments
Sequenom Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. The company reported revenue of $38.5 million for the first quarter of 2013, an increase of 158% compared to revenue of $14.9 million for the first quarter of 2012. Loss from operations was $27,014,000, loss before income taxes was $29,348,000 against $24,245,000 and $24,421,000 respectively a year ago. Net loss for the first quarter of 2013 was $29.4 million, or $0.26 per basic and diluted share, as compared to net loss of $24.4 million, or $0.22 per basic and diluted share, for the same period in 2012. Net cash used in operating activities was $19.7 million for the first quarter of 2013, compared to $23.3 million in the same period in the prior year.
Sequenom Inc., Q1 2013 Earnings Call, May 09, 2013
Sequenom Inc. announced that they will report Q1, 2013 results at 5:00 PM, Eastern Standard Time on May 09, 2013
| Recently Viewed | |||
| SQNM:US | $3.91 USD | -0.15 | |
| Company | Last | Change |
| Antares Pharma Inc | $3.96 USD | -0.10 |
| Fluidigm Corp | $17.14 USD | -0.61 |
| Palomar Medical Technologies Inc | $13.44 USD | -0.13 |
| Staar Surgical Co | $8.58 USD | -0.20 |
| SurModics Inc | $26.13 USD | +0.17 |
| View Industry Companies | ||
Industry Analysis
SQNM
Industry Average
| Valuation | SQNM | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 4.2x |
|
| Price/Book | 21.1x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 1.5x |
|
Post a JobJobs
- San Diego, CA | SequenomPosted: May 22
- San Diego, CA | SequenomPosted: May 17
- San Diego, CA | SequenomPosted: May 17
- San Diego, CA | SequenomPosted: May 11
Sponsored Financial Commentaries
Sponsored Links
To contact SEQUENOM INC, please visit www.sequenom.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.








